Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03380351|
Recruitment Status : Not yet recruiting
First Posted : December 21, 2017
Last Update Posted : March 20, 2018
|Condition or disease||Intervention/treatment|
|Anemia, Sickle Cell||Behavioral: SCDIC interventions Behavioral: SCDIC control groups|
|Study Type :||Observational|
|Estimated Enrollment :||24 participants|
|Official Title:||The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults With Sickle Cell Disease: From Clinic to the Community and Back|
|Anticipated Study Start Date :||April 2, 2018|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||June 30, 2020|
Careful detail the intervention components and the implementation strategies (i.e., the mechanisms by which the interventions are being delivered in usual care) being developed by the consortium.
Behavioral: SCDIC interventions
The research team will characterize the intervention components and their implementation strategies.
SCDIC control groups
Careful detail the control conditions of each of the SCDIC sites for each of the interventions being developed.
Behavioral: SCDIC control groups
The research team will characterize the control settings, including patients, providers and organization.
- SCDIC Framework of Interventions [ Time Frame: 2 years ]Detailed descriptions of the interventions being developed by the SCDIC including a) entity, or entities, targeted by the intervention; (b) functional domains targeted by the interventions; and (c) delivery system characteristics
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03380351
|Contact: Ana Baumann, PhD||314 935 email@example.com|
|Contact: Allison King, MD, MPH, PhDfirstname.lastname@example.org|
|United States, Missouri|
|Washington University in St. Louis||Not yet recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Ana Baumann, PhD 314-935-3585 email@example.com|
|Principal Investigator:||Ana Baumann, PhD||Washington University School of Medicine|